Stocks
Gilead Sciences, Inc.GILD
NASDAQHealthcareBiotechnology$144.99-0.15%
A biopharmaceutical company focused on antiviral therapies, oncology, and cell therapy, with a leading portfolio in HIV treatment and prevention. Revenue is driven primarily by its HIV franchise, alongside growing contributions from oncology and liver disease products. Investors track the company for its patent cycle management, pipeline development, and capital allocation strategy, including acquisitions and share repurchases.
Market Cap: $180.0B52W Range: $93.37 – $157.29
Congressional Interest in Gilead Sciences, Inc. (GILD)
23 members of Congress have disclosed 50 trades in Gilead Sciences, Inc. (GILD), a Healthcare company. The buy/sell breakdown shows 22 purchases versus 28 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
23
Buys
22
Sells
28
Who in Congress Is Trading GILD?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-09-25 | Shelley M Capito | buy | $1K – $15K |
| 2018-07-17 | Earl Blumenauer | buy | $1K – $15K |